Moreover, SRX3305 was substantially more cytotoxic than Ibrutinib to these MCL cells due to the concurrent inhibition of not only BTK but also two additional targets, PI3K and BRD4. The gene discussed is BRD4; the disease is mantle cell lymphoma.